| Theme | The frontline of Crohn's disease treatment | |
|---|---|---|
| Title | Newly developing therapies for patients with Crohn's disease | |
| Publish Date | 2016/03 | |
| Author | Hiroshi Nakase | Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, |
| [ Summary ] | The efficacy of anti-tumor necrosis factor (TNF)-agents are generally acknowledged ; however, up to 30 % of patients with inflammatory bowel diseases (IBDs) do not respond to induction therapy with this drug (primary non-responders), and a significant proportion loses response over time (secondary non-responders). Therefore, there remains an unmet need for new treatment choices for these patients. Recent clinical trials with novel drugs demonstrated potent effects on patients with IBD. These drugs include small molecules that interfere with intracellular signaling pathways, and therapeutic antibodies directed against extracellular targets, such as pro-inflammatory cytokines and receptors. This article aims to review the efficacy and safety data from clinical trials that describe new developing drugs for patients with Crohn's disease. | |